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Introduction
The name Ferroportin Disease (FD) refers to a clinical entity that differs from all
other known forms of hereditary iron overload, including hemochromatosis (HC)
[synonymous for hereditary hemochromatosis (HH)], i.e. the syndrome due to
either HFE or non-HFE hemochromatosis gene mutations.1 In humans, a number
of genetic disorders associate with systemic iron overload (Table 1) while others
are  caused by iron misdistribution and are associated with the regional accumula-
tion of iron in subcellular compartments (e.g. mitochondria in Friedreich ataxia) or
certain cell types and organs (e.g. basal ganglia in neuroferritinopathy) (Table 1). In
strict terms, the latter disorders may not all qualify as true iron-overload states, as
the total body iron content may not be increased. FD, which today accounts for
one of the commonest forms of hereditary iron overload disorder besides HFE-
hemochromatosis, is characterized by a unique pathogenic basis and clinical pres-
entation and, unlike HC, has been reported worldwide, regardless of ethnicity. 
Ferroportin Disease (phenotype MIM number 606069, gene/Locus;  MIM num-
ber 604653; https://www.omim.org/entry/606069?search=ferroportin%20dis-
Ferroportin Disease (FD) is an autosomal dominant hereditary ironloading disorder associated with heterozygote mutations of the fer-roportin-1 (FPN) gene. It represents one of the commonest causes of
genetic hyperferritinemia, regardless of ethnicity. FPN1 transfers iron
from the intestine, macrophages and placenta into the bloodstream. In
FD, loss-of-function mutations of FPN1 limit but do not impair iron
export in enterocytes, but they do severely affect iron transfer in
macrophages. This leads to progressive and preferential iron trapping in
tissue macrophages, reduced iron release to serum transferrin (i.e. inap-
propriately low transferrin saturation) and a tendency towards anemia at
menarche or after intense bloodletting. The hallmark of FD is marked
iron accumulation in hepatic Kupffer cells. Numerous FD-associated
mutations have been reported worldwide, with a few occurring in differ-
ent populations and some more commonly reported (e.g. Val192del,
A77D, and G80S). FPN1 polymorphisms also represent the gene variants
most commonly responsible for hyperferritinemia in Africans.
Differential diagnosis includes mainly hereditary hemochromatosis, the
syndrome commonly due to either HFE or TfR2, HJV, HAMP, and, in rare
instances, FPN1 itself. Here, unlike FD, hyperferritinemia associates with
high transferrin saturation, iron-spared macrophages, and progressive
parenchymal cell iron load. Abdominal magnetic resonance imaging
(MRI), the key non-invasive diagnostic tool for the diagnosis of FD,
shows the characteristic iron loading SSL triad (spleen, spine and liver). A
non-aggressive phlebotomy regimen is recommended, with careful mon-
itoring of transferrin saturation and hemoglobin due to the risk of ane-
mia. Family screening is mandatory since siblings and offspring have a
50% chance of carrying the pathogenic mutation.
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ease&highlight=ferroportin%20disease) is due to patho-
genic (usually missense) mutations of the ferroportin1
gene (FPN1; SLC40A1) which encodes the only iron
exporter so far identified in mammals;2-4 lack-of-function
mutations impair the iron-export capability of FPN1, par-
ticularly in cells with high iron turnover, such as tissue
macrophages. Unlike the mutations causing FD, other rare
mutations of FPN1 (such as N144H, C326Y, C326S and
C326F),5-8 do not impair protein expression at the cell
membrane or its iron export capability, but make FPN1
resistant to the inhibitory effect of hepcidin, the physio-
logical FPN1 inhibitor (see below under Pathogenesis).
This causes unchecked iron export activity of FPN1; the
resulting clinical disorder is different from FD and indistin-
guishable from other forms of hereditary HC (Tables 1
and 2). 
Definition and classification
The OMIM database classifies the two forms of heredi-
tary iron overload due to FPN1 mutations within the same
taxonomic category as  “hemochromatosis type 4”
(https://www.omim.org/entry/606069?search=ferro-
portin%20disease&highlight=ferroportin%20disease).
Similar terminology has then been adopted by Orphanet
with the inclusion of two subcategories: hemochromato-
sis type 4A (referring to classic FD due to lack-of-function
FPN1 mutations) and hemochromatosis type 4B (referring
to FD due to gain-of-function FPN1 mutations)
( h t t p : / / w w w . o r p h a . n e t / c o n s o r / c g i -
bin/OC_Exp.php?Lng=EN&Expert=139491). These classi-
fications have been incorporated into recent publications,
with some variants.9,10 Disease naming and classification
(taxonomy) can vary depending on different criteria, such
as pathogenic genes, mechanisms, clinical manifestations,
etc. Ideally, disease taxonomy (and names) should also
help clinicians to recognize, diagnose, and cure diseases.
In this context, the taxonomy adopted by OMIM and
Orphanet, by embracing two pathogenically and clinically
different disorders caused by mutations in the same gene
under the term “hemochromatosis”, may fail to reach
those objectives. Over the past decades, the term
hemochromatosis has been inconsistently used in the lit-
erature and in clinical practice to imprecisely refer to: i)
any form of body iron overload; ii) tissue iron overload
causing organ damage and disease; iii) genetically deter-
mined iron overload; and, recently, iv) HFE-related iron
overload.11 Recent discoveries in the field have shown
that, regardless of the underlying genetic defect, a number
of hereditary iron loading disorders (i.e. those due to loss-
of-function mutations of HFE, TfR2, HJV, HAMP and gain-
of-function mutations of FPN1)   belong to the same syn-
dromic entity as they share the pathogenic basis (lack of
hepcidin function-activity), biochemical expressivity (high
transferrin saturation and high serum ferritin), liver
pathology features (iron accumulation in parenchymal
cells with iron-spared Kupffer cells until late stage), dam-
age and disease of distinct target organs (liver, heart,
endocrine glands, joints),  and the therapeutic approach
with optimal response to phlebotomy.11 As discussed in
the following sections, each individual feature reported
above is different in classic FD.1 Therefore, using the term
“hemochromatosis” for the classic FD or the term
“Ferroportin Disease” for FPN1-associated HC, is mislead-
ing, particularly for clinicians, since clinical suspicion,
diagnostic strategy and management differ profoundly.
Based on these considerations, and on our present under-
standing of the pathogenesis  and clinical manifestations
of these disorders, it is proposed that the disorder due to
lack-of-function mutations of FPN1 is termed “Ferroportin
Disease”, as originally described,1 and the disorder due to
gain-of-function FPN1 mutations is termed “FPN-1 associ-
ated hemochromatosis” (Table 1). Instead, in analogy with
other protein-related classifications (e.g. ferritinopathies;
hemoglobinopathies), both disorders due to lack- and
gain-of-function mutations of FPN1 may well be included
in a broader taxonomic category named “ferro-
portinopathies”. 
Historical aspects
In 1996, the HFE hemochromatosis gene, whose C282Y
homozygote mutation is responsible for most cases of HH
in Caucasians, was identified.12 Soon after, it became
apparent that not all hereditary iron overload disorders
could be explained by HFE mutations, particularly in
Southern Europe, where an active search for other genes
linked to genetic iron overload flourished.  From 2000 to
2004, all known non-HFE genes associated so far with
HC, namely transferrin receptor 2 (TfR2),13 FPN1,5 hep-
cidin (HAMP),14 and hemojuvelin (HJV)15 were identified. 
A few years earlier, in 1999, a distinct and somehow
unusual phenotype had been reported in a large family
with hereditary iron overload from Italy. Selective iron
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Table 1. Human hereditary disorders associated with iron overload and iron mis-distribution.
                                                             Iron overload                                                                                                Iron mis-distribution
                               Disorder/cause                          Pattern of iron accumulation                           Disorder/cause             Pattern of iron accumulation
Hereditary hemochromatosis (HFE-TfR2-,                   Systemic (iron accumulation in                 X-linked sideroblastic anemias      Systemic (mitochondria)
HJV-, HAMP-, FPN1-associated)                                                  parenchymal cells)                                                         
Ferroportin Disease                                                  Systemic (preferential iron accumulation                    Friedreich ataxia                   Systemic (mitochondria)
                                                                                                               in macrophages)
                                 Aceruloplasminemia                                               Systemic                                                Neuroferritinopathy                        Regional (brain)
                                     Atransferrinemia                                                  Systemic                                                                   
                                    DMT-1 deficiency                                     Regional (mainly liver)                                                      
                       H-ferritin-related iron overload                                     Systemic                                                                   
Hereditary iron-loading anemias with inefficient                 Systemic (early iron 
                                       erythropoiesis                                  accumulation in hepatocytes 
                                                                                               due to increased iron absorption)
loading of liver macrophages, hyperferritinemia co-exist-
ing with normal-low transferrin saturation, and tendency
to anemia after intense phlebotomy were the hallmarks of
the disorder.16 In 2001, all affected family members were
reported to be heterozygous for a c. 230 C→A substitu-
tion resulting in the replacement of alanine 77 with aspar-
tate in FPN1.17 This entity was subsequently named FD.1
On the other hand, FPN1-related HC, due to a gain-of-
function mutation of FPN1 (p.N144H), was first reported
by Njajou et al. in 2001.5 Yet, it is worth mentioning that
the first clinical description of an “autosomal dominant”
form of classic HC had been already reported by Eason et
al. in a Melanesian kindred in 1990.18 In this same popu-
lation, Arden et al.19 have later linked the HC  phenotype
to the NI44T gain-of-function mutation of FPN1.
Ferroportin biology and physiology and FD
FPN1, the product of the FPN1 (SLC40A1) gene, trans-
fers iron from the external milieu (i.e. maternal blood or
intestinal lumen) and from internal sites of iron storage
and recycles it into the bloodstream. In fact, it is highly
expressed in liver and spleen macrophages, the luminal
site of enterocytes and placental syncytiotrophoblasts.2-4
FPN1 is regulated at different levels by a number of fac-
tors, including  transcriptionally by heme,20 translationally
by the iron-regulatory proteins (IRPs),21 and posttransla-
tionally mainly by hepcidin, the iron hormone. Hepcidin
is produced by the liver in response to iron, inflammation,
and a variety of stressors.22-25 Hepcidin binds to the extra-
cellular loop of FPN1 and triggers its ubiquitinylation on
lysine residues located in the intracellular domain leading
to internalization and degradation in lysosomes.26-28 This
mechanism allows a finely-tuned control of iron efflux
from enterocytes and macrophages toward the blood-
stream when more iron is needed during active erythro-
poiesis (in this case, hepcidin synthesis is inhibited by ery-
throid signals), or blood iron must be controlled due to
pathogen proliferation/growth or incipient iron overload
(here hepcidin synthesis is induced by inflammatory or
iron mediators, respectively) (reviewed by Drakesmith,
Nemeth and Ganz29).
FPN1 topology and membrane organization have long
been addressed with controversial results concerning
localization of the N- and C-terminal extremities and
number of transmembrane segments.30-39 Recently, an
inward-open conformation of the transporter has been
predicted,34,37 with a cluster of residues lying in the central
core of the protein important for iron traffic and consistent
with an iron-binding site37 and residues involved in hep-
cidin binding fully accessible in the outward-open
model.37 The inward-open form may represent the resting
state of the protein, and the outward-open state as a con-
formation attainable only in the presence of intracellular
iron, i.e. when FPN1 shuttles between the two conforma-
Table 2. Main features of Ferroportin Disease and other hereditary iron overload disorders in humans.
Disorder                           Affected gene                 Known or                 Epidemiology               Genetics            Mechanism for       Clinical                Main             Clinical
                                    (symbol / location)       postulated gene                                                                     increased cellular      onset                clinical            course
                                                                         product function                                                                         iron deposits        (decade)         manifestation            
I. Ferroportin Disease       Solute carrier                Iron exporter            Affects Caucasians           Autosomal              Iron retention             Any              • Liver disease          Mild
                                       family 40 (iron-regulated   (SLC40A1 / 2q32)      and non Caucasians           dominant            due to decreased                             • Marginal anemia
                                        transporter), member 1           from cells                                                                                                 iron export
                                                                                                 including
                                                                                             macrophages, 
                                                                                              enterocytes, 
                                                                                      syncityotrophoblasts                       
II. Hemochromatosis     Hemochromatosis       Hepcidin regulator       Affects Caucasians                                                                                    4th-5th
                                            gene (HFE / 6p21.3)                                                of North European                                                         
                                                                                                                                            descent                                                                    
                                                                                                                                                                                 Autosomal                           
                                          Transferrin-receptor 2             Hepcidin                           Affects                       recessive                                                                                                                 Mild-
                                                   (TfR2 / 7q22)                      regulator                   Caucasians and                                                                                       3rd-4th                                                 severe
                                                                                                                                     non Caucasians                                                Increased iron                                                                             
                                                  Solute carrier                Iron exporter            Affects Caucasians                                              accumulation                                                                              
                                                family 40 (iron-          from cells including    and non Caucasians                                           in parenchymal                                 •Liver Disease              
                                         regulated transporter),       macrophages,                                                          Autosomal                cells due to              4th-5th                        • Arthropathy                         
                                                     member 1                    enterocytes,                                                           dominant                   increased                                    • Cardiomyopathy           
                                              (SLC40A1 / 2q32)       syncityotrophoblasts                                                                                    transferrin and                               • Endocrinopathy
                                         Hepcidin antimicrobial          Degradation             Affects Caucasians                                            non-transferrin                
                                                        peptide                      of ferroportin          and non Caucasians                                               bound iron
                                               (HAMP /19q13.1)         and downregulation                                                    Autosomal                     import                   2nd-3rd       • Hypogonadism and        
                                                                                             of iron efflux                                                           recessive                                                                          cardiomyopathy       Severe
                                                                                                from cells                                                                                                                                                            • Liver disease
                                                   Hemojuvelin                       Hepcidin                Affects Caucasians
                                                    (HJV/ 1p21)                       regulator               and non Caucasians                                                                                                                                                    
III. Aceruloplasminemia    Ceruloplasmin                   Iron efflux              Affects Caucasians           Autosomal                 Decreased               2nd-3rd             • Neurological       Severe
                                                (CP / 3q23-q25)                   from cells             and non Caucasians           recessive                  iron efflux                                       manifestations
                                                                                                                                                                                                                                                                                     • Anemia                   
IV. A (hypo)transferrinemiaTransferrin           • Iron transport in the   Affects Caucasians           Autosomal             Increased iron           1st-2nd                    Anemia               Severe
                                                     (Tf / 3q21)                     bloodstream           and non Caucasians           recessive                       influx                         
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tions (Figure 1A). The selective binding of hepcidin to the
outer-facing conformation would, therefore, guarantee
that FPN1 degradation can occur only when intracellular
iron is abundant37 and actively pumped through the chan-
nel38 (Figure 1B). Recently, the crystal structures of a bac-
terial homolog of FPN1, BbFPN, has been resolved in both
the outward- and inward-facing states, and a homology
model with human FPN1 has been developed.39
According to the Au, FPN1 has 12 TM helices, as previous-
ly predicted,32 and is divided into two halves, one forming
the N lobe, the other the C lobe connected by a long
cytosolic loop, with a central cavity between the lobes
that is open towards the extracellular side and not accessi-
ble from the intracellular side (Figure 1A). FPN1 undergoes
an intra-domain conformational rearrangement during the
transport cycle. When hepcidin enters the central cavity
between the N and C lobes, and interacts with the hep-
cidin-binding site located on the C lobe, it elicits two
effects: a) it increases the accessibility of the intracellular
loops that harbor the ubiquitination sites  to the ubiquitin
ligases; and b) it arrests the conformational transition of
FPN1  from the outward-facing state to the inward-facing
state, inhibiting the access of iron from the cytoplasm to
the substrate-binding site within the intracellular gate
(Figure 1B).39
Molecular pathogenesis
The general pathophysiological basis of  FD is well
defined and relies on the impaired iron export from the
iron storage/recycling site (particularly macrophages)
towards the bloodstream. Figure 2 shows the basic iron
transport defect of the FD as opposed to FPN1-associated
Ferroportin Disease
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Figure 1. Biology of ferroportin and postulated pathobiology of Ferroportin Disease (FD). (A) Structure-function relationship of iron-export ferroportin activity.39 (B)
Putative mechanisms of hepcidin binding to FPN and its degradation.39 (C) Postulated basis for FD. (Upper panel) In cells undergoing relatively low iron flux, such as
enterocytes, the product of the FPN wild-type allele is able to reach the plasma membrane and export iron. For clarity, mutated FPN1 was not depicted at the cell
surface: based on previous in vitro work, it has been postulated that some mutant FPN1 can still reach the cell surface and preserve some iron-transport compe-
tence, but this is still controversial. (Lower panel) In cells undergoing high iron turnover, such as macrophages, increased requests for iron export impose high
demands on FPN traffic leading to a 'traffic jam' within the endocytic/plasmamembrane and degradation compartments and inappropriately low wild-type allele prod-
uct targeting to the cell membrane.54 (D) Postulated effect of FPN mutations that affect formation of the intracellular gate and access to the iron binding site.39
HC. In the latter cases, as discussed above, mutations that
affect the hepcidin binding site and or FPN1 ubiquitination
result in reduced FPN 'sensitivity' to hepcidin, leading to
the FPN1-related HC phenotype. This has been nicely
exemplified by an informative murine model correspon-
ding at the mutation of the hepcidin binding site.40
In spite of these advances, the molecular pathogenesis
of FD has long been elusive. A number of in vitro studies,
mostly using over-expressed exogenous wild-type and
mutant FPN1 in a variety of cell lines, have investigated
FPN1 biology and function and the effect of different
FPN1 mutants on protein traffic and iron-transfer capabil-
ity, although with conflicting results, depending on the
cell line or methodology used.30-32,34,35,38,41-47
In this context, it has been actively debated whether
FPN1 haplo-insufficiency would explain FD or whether
the disease results from a dominant-negative effect. It has
been argued that if haplo-insufficiency was the explana-
tion for  FD, then nonsense mutations should also result in
the disorder; however, so far, the vast majority of reported
mutations in FD are missense mutations.48 In addition, a
targeted gene deletion in the murine Fpn1 gene has little
effect in heterozygous animals,49 whereas the flatiron (ffe)
mouse with a missense mutation in Fpn1 that affects its
localization and iron export activity when over-expressed
in vitro, present a phenotype similar to human patients.50 In
studies using exogenous tagged protein in vitro, Fpn1 forms
multimers and mutant Fpn1 prevents cell membrane local-
ization of wild-type Fpn1.33,42,50 A multimeric protein,
through a dominant-negative effect, would better explain
the autosomal dominant trait of FD. However, other stud-
ies from different groups have provided experimental evi-
dence to support the opposite conclusion and showed that
Fpn1 is a monomer in cultured cells35,51,52 and in vivo.53
More recently, Sabelli et al.,54 using for the first-time cul-
tured macrophages from FD patients, found that endoge-
nous FPN1 shows a similar localization to that in donor
macrophages, except for greater accumulation in lyso-
somes, suggesting a higher degradation rate of mutant
FPN1. Unexpectedly, and contrary to previous studies
using over-expressed mutant protein in cell lines, FPN1 in
FD macrophage circulates in the early endocytic compart-
ment, does not multimerize, it reaches the plasma mem-
brane, is iron-transport competent (although to a lesser
extent than normal macrophages), and is promptly inter-
nalized and degraded upon exposure to hepcidin.
However, when FD macrophages are exposed to large
amounts of heme iron, in contrast to donor macrophages,
FPN1 can no longer reach the cell surface, leading to
marked intracellular iron retention. Based on these obser-
vations, a model of FD has been proposed in which FPN1
monomers, in spite of the fact that half proteins are mutat-
ed, can still reach the cell surface and export iron in cells
that are exposed in vivo to a relatively low flux of iron,
such as enterocytes (Figure 1C).54 On the contrary, in cells
undergoing high iron turnover in vivo, such as tissue
macrophages, sufficient FPN1 is prevented from reaching
the plasma membrane, possibly due to a 'traffic jam' in the
degradation and/or endocytic cycling pathways. This
model is consistent with the clinical manifestation of FD
characterized by early iron accumulation in hepatic
Kupffer cells  and normal transferrin saturation, indicating
that mutant FPN1 activity does not limit intestinal iron
transfer; the latter becomes critically low in young females
at menarche or after aggressive phlebotomy, when high
iron demands for erythropoiesis likely impose increased
FPN1 traffic/cycling within tissue macrophages.1,16,17 (See
below under Clinical Manifestations and Diagnosis and
Treatment). This study did not address the question as to
whether mutant or only wild-type FPN1 reaches the plas-
ma membrane and whether mutant-FPN1 is transport
competent. Previous studies have not been conclusive.
Exogenously expressed p.A77D and p.Val162del FPN1
mutants have been found to be iron-transport incompe-
tent in all studies, but able to reach the cell membrane in
some,34,35,38,41,43 and not in others.30,31 The p.G80S FPN1
mutant has been localized at the cell surface in two pub-
lished studies,43,55 and found iron transport competent in
one55 and incompetent in the other.43
According to Taniguchi et al.,39 the mutation sites asso-
ciated with  FD are mainly mapped onto the inter-lobe
interface, mostly on the intracellular side, and form the
intracellular gate. These mutations would, therefore,
destabilize the inter-lobe interactions, thereby affecting
the stable formation of the intracellular gate and reducing
the iron transport activity of FPN1 (Figure 1D). It is possi-
ble that different mutants differently affect iron transport
capability of FPN1; while this may be better overcome by
the normal allele product in cells with low iron turnover
such as enterocytes or hepatocytes, it may be further ham-
pered in cells like macrophages where the additional 'traf-
fic jam' in the endocytic-plasmamembrane compartment
will aggravate the basic defect (see above). 
Genetics and epidemiology
A list of published mutations associated with FD and
FPN1-related HC is reported in Table 3.5-8,17,43,56-102
Numerous mutations of the FPN1 gene have been identi-
fied so far in probands with the classic FD phenotype of
French-Canadian, Melanesian, Thai, Japanese and
European heritages.
A few common FPN1 mutations have been reported in
independent pedigrees, in different countries (e.g.
Val192del;56,60,72-79,92 A77D,17,59,60 G80S.43,55,56,61-63 It is now
believed that the most frequently reported FPN1 muta-
tions, such as the p.Val162del,  are more frequently iden-
tified than other SLC40A1 mutations because they have
occurred multiple times in isolated populations rather
than occurring once and spreading to different popula-
tions, as indicated by the identification of a de novo
p.Val162del variant in an isolated case of FD.79
FPN1 variants are highly prevalent in African popula-
tions. The first prevalent FPN1 variant reported in Africans
and Black Americans was the common Q248H polymor-
phism (p.Gln248His).82,83,100-102 Interestingly, global analysis
of variants in the SLC40A1 gene (which includes muta-
tions associated with both the FD and FPN1-associated
HH) revealed an allele frequency of 0.0364%, giving a pre-
dicted pathogenic genotype carrier rate of 1 in 1373, a fig-
ure that approaches the frequency of HFE-HC.103 This was
largely due to the relatively high allele frequencies for two
SLC40A1 variants (p.Asp270Val84,85 and p.Arg371Trp56) in
the African populations; the predicted SLC40A1 patho-
genic genotype carrier rate of these two variants is 1 in 197
among the African population.103 The Q248H,101,102 the
p.Asp270Val and the p.Arg371Trp and other FPN1 poly-
morphic variants84 may also predispose to iron overload;
but no clear evidence for this has been provided (e.g. lack
of functional studies), while the possibility remains that,
because of the small sample size, these observations could
A. Pietrangelo
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Table 3. Disease-associated mutations of the FPN1 gene. 
Gene SLC40A1 (RefSeq NM_014585.5, NP_055400.1)
A. Ferroportin disease
      Nucleotide change                Amino acid change              Type of variation*                          Phenotype                                 Reference
1.                      c.134C>A                             p.Ala45Glu                                 Missense                              ferroportin diseasea                                      56
2.                      c.205G>A                            p.Ala69Thr                                 Missense                               ferroportin disease                                       57
3.                      c.206C>T                             p.Ala69Val                                  Missense                              ferroportin diseasea                                      56
4.                      c.212C>T                            p.Ser71Phe                                Missense                              ferroportin diseasea                                      56
5.                      c.214G>T                            p.Val72Phe                                 Missense                               ferroportin disease                                       58
6.                      c.230C>A                             p.Ala77Asp                                 Missense                               ferroportin disease                                  17,59,60
7.                      c.238G>A                            p.Gly80Ser                                 Missense                               ferroportin disease                            43,55,56,61-63
8.                      c.239G>T                             p.Gly80Val                                  Missense                               ferroportin disease                                       64
9.                      c.252C>G                            p.Asp84Glu                                 Missense                               ferroportin disease                                       91
10.                    c.262A>G                            p.Arg88Gly                                 Missense                               ferroportin disease                                    56, 65
11.                    c.263G>C                            p.Arg88Thr                                 Missense                               ferroportin disease                                       66
12.                    c.386T>C                           p.Leu129Pro                               Missense                               ferroportin disease                                      67
13.                    c.454A>T                            p.Ile152Phe                                Missense                               ferroportin disease                                       68
14.                    c.469G>A                           p.Asp157Asn                               Missense                               ferroportin disease                                       58
15.                    c.469G>T                           p.Asp157Tyr                                Missense                               ferroportin disease                                       69
16.                    c.470A>C                            p.Asp157Ala                                Missense                               ferroportin disease                                       70
17.                    c.470A>G                           p.Asp157Gly                                Missense                               ferroportin disease                                  56,69,71
18.                    c.473G>T                           p.Trp158Leu                               Missense                               ferroportin disease                                       56
19.                    c.474G>T                           p.Trp158Cys                                Missense                               ferroportin disease                                       47
20.                    c.484_486del                      p.Val162del                                 Deletion                                ferroportin disease                            56,60,72-79,92
21.                    c.521A>T                            p.Asn174Ile                                Missense                               ferroportin disease                                       61
22.                    c.532C>G                           p.Arg178Gly                                Missense                               ferroportin disease                                       77
23.                    c.533G>A                           p.Arg178Gln                                Missense                               ferroportin disease                                    56,65
24.                    c.539T>C                            p.Ile180Thr                                Missense                               ferroportin disease                                       66
25.                    c.542A>T                            p.Asp181Val                                Missense                               ferroportin disease                                  56,64,69
26.                    c.546G>T                           p.Gln182His                                Missense                               ferroportin disease                                    56, 71
27.                    c.553A>G                           p.Asn185Asp                               Missense                               ferroportin disease                                    56, 80
28.                    c.554A>C                           p.Asn185Thr                                Missense                              ferroportin diseasea                                      56
29.                    c.610G>A                           p.Gly204Ser                                Missense                              ferroportin diseasea                                      56
30.                    c.689C>A                           p.Thr230Asn                               Missense                              ferroportin diseasea                                      69
31.                    c.695C>A                            p.Ala232Asp                                Missense                               ferroportin disease                                       81
32.                    c.698T>C                           p.Leu233Pro                               Missense                               ferroportin disease                                    68,69
33.                    c.744G>T                           p.Gln248His                                Missense                              ferroportin diseasea                            82,83,100-102
34.                    c.797T>C                           p.Met266Thr                               Missense                              ferroportin diseasea                                      69
35.                    c.800G>A                           p.Gly267Asp                                Missense                               ferroportin disease                                       64
36.                    c.809A>T                            p.Asp270Val                                Missense                               ferroportin disease                                    84,85
37.                    c.968G>T                            p.Gly323Val                                 Missense                               ferroportin disease                                       71
38.                    c.1035G>C                        p.Leu345Phe                               Missense                              ferroportin diseasea                                      69
39.                    c.1051A>G                          p.Ile351Val                                 Missense                              ferroportin diseasea                                      69
40.                    c.1111C>T                          p.Arg371Trp                                Missense                              ferroportin diseasea                                      56
41.                    c.1112G>A                         p.Arg371Gln                                Missense                              ferroportin diseasea                                      56
42.                    c.1328C>T                         p.Pro443Leu                               Missense                              ferroportin diseasea                                      69
43.                    c.1402G>A                         p.Gly468Ser                                Missense                              ferroportin diseasea                                      86
44.                    c.1466G>A                         p.Arg489Lys                                Missense                               ferroportin disease                                       46
45.                    c.1467A>C                         p.Arg489Ser                                Missense                               ferroportin disease                                       87
46.                    c.1468G>A                         p.Gly490Ser                                Missense                               ferroportin disease                                  56,65,69
47.                    c.1469G>A                         p.Gly490Asp                                Missense                               ferroportin disease                                    88, 69
48.                    c.1520A>G                         p.His507Arg                                Missense                              ferroportin diseasea                                      89
49.                    c.1681A>G                         p.Arg561Gly                                Missense                              ferroportin diseasea                                      90
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be attributable to chance or that the polymorphisms iden-
tified may be in linkage disequilibrium with other disease-
causing loci. Yet, taken together, the collected data make
FPN1 the gene most frequently associated with hereditary
hyperferritinemia in Africans. 
Clinical manifestations and diagnosis
As discussed, FD is caused by loss-of-function muta-
tions in FPN1. These mutations impair iron export, partic-
ularly from reticuloendothelial macrophages. The result is
iron accumulation in macrophages of the spleen, liver, and
bone (reflected by high levels of SF) (Figure 3). At liver his-
tology, parenchymal cells of these organs are largely
spared (Figure 3), but discrete hepatocytic iron deposits
are also appreciable, due to defective FPN1 activity in
hepatocytes, even at early stages.16 Clinical presentation
appears heterogeneous, but overall expressivity is milder
than classic HC, and the associated liver disease is usually
not as severe (Table 2 and Figure 3).1,16,17,56 As occurs in clas-
sic forms of HFE HC, also in the FD host factors (menses,
blood loss, etc.), co-inheritance of mutations of other iron-
genes or variants in genes associated to antioxidant
defense and organ fibrosis, and associated pathological
conditions (metabolic syndrome, viral hepatitis, etc.) may
all affect the phenotype. Hypochromic anemia is not
uncommon in young menstruating females. 
Owing to the mild clinical expressivity reported in the
literature, doubts have been raised on the penetrance of
the genetic defect and the rationale for iron-removal ther-
apy. However, there is limited and usually not detailed
clinical information in the published reports; this, and the
lack of prospective studies, still hamper our understanding
of the actual clinical impact of the disorder. In the only
report published so far, 6 members of the pedigree in
which FD was first described16 were followed for 11-24
years.104 The proband, aged 83, who had carried an occult
HBV infection since the age of 56, developed a liver cancer
in a non-cirrhotic liver after discontinuation of a 20-year
long phlebotomy program; 2 siblings, who had also inter-
rupted treatment, showed a fibrosis progression. These
clinical data, while of interest, do not allow  definite con-
clusions to be drawn as to a pathogenic link between iron
accumulation in FD and liver damage and disease. 
The hallmark of classic FD is marked iron accumulation
in Kupffer cells (Figure 3). Kupffer cells are vital to the pro-
duction of fibrogenic mediators, to immunological tumor
surveillance, and disposal of transformed hepatocytes.105
Selective and massive iron overload may impair these
activities and favor fibrogenesis and carcinogenesis.
Moreover, as discussed above, hepatocytic iron accumula-
tion also takes place in FD, although to a much lesser
extent than in HFE- and non-HFE HC, and the established
pro-oxidant damaging activity of iron in parenchymal cells
may also contribute to disease progression. 
Unlike HFE-HC, the pattern of inheritance of  FD is
autosomal dominant. Therefore, either parent carries the
pathogenic mutation of FPN1 and presents with unex-
plained hyperferritinemia. In addition, the proband carries
a 50% risk of having an affected child. The disease must
be suspected in any individual with unexplained hyperfer-
ritinemia and low-normal transferrin saturation (TS), or
non-parenchymal cell siderosis at liver biopsy or liver and
spleen iron accumulation at MRI (Table 4).  
Hyperferritinemia in FD appears very early in life, and
unexplained hyperferritinemia with normal TS in a child
should prompt  MRI evaluation to evaluate iron accumu-
lation in liver, spleen and bone marrow106 (see below).
Figure 4 shows a proposed algorithm for the diagnosis of
FD. If hyperferritinemia associates with high TS (as con-
firmed in at least two sequential determinations) but in the
absence of anemia, a typical picture of HFE- and non HFE-
HC (including FPN1-associated HC due to gain-of-function
FPN1 mutations)  is ruled out a priori. If hyperferritinemia
associates with high TS and anemia, a typical picture of
hereditary hemoglobinopathies and red cell defects or
atransferrinemia, FD is again ruled out (Figure 4).
On the contrary, in subjects with increased serum fer-
ritin and low or normal TS, the workup should focus on
common causes of secondary hyperferritinemia and other
rare causes of hereditary hyperferritinemia to confirm the
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B. Ferroportin1-associated hemochromatosis 
1.                      c.-59_-45del                                                                             Deletion                                 hemochromatosis                                        65
                                                                                                                  (heterozygous state)
2.                      c.190T>A                             p.Tyr64Asn             Missense (heterozygous state)           hemochromatosisb                                        93
3.                      c.190T>C                             p.Tyr64His             Missense (heterozygous state)            hemochromatosis                                        94
4.                      c.430A>C                           p.Asn144His           Missense (heterozygous state)           hemochromatosisb                                         5
5.                      c.430A>G                           p.Asn144Asp           Missense (heterozygous state)           hemochromatosisb                                         6
6.                      c.431A>C                           p.Asn144Thr           Missense (heterozygous state)           hemochromatosisb                                        19
7.                      c.718A>G                           p.Lys240Glu            Missense (heterozygous state)            hemochromatosis                                        95
8.                      c.977G>A                           p.Cys326Tyr            Missense (heterozygous state)            hemochromatosis                                     96, 97
9.                      c.977G>C                           p.Cys326Ser           Missense (heterozygous state)           hemochromatosisb                                         7
10.                    c.977G>T                           p.Cys326Phe           Missense (heterozygous state)           hemochromatosisb                                         8
11.                    c.1014T>G                         p.Ser338Arg           Missense (heterozygous state)           hemochromatosisb                                        98
12.                    c.1502A>G                         p.Tyr501Cys            Missense (heterozygous state)            hemochromatosis                                        99
13.                    c.1510G>A                         p.Asp504Asn           Missense (heterozygous state)            hemochromatosis                                        69
14.                    c.1520A>G                         p.His507Arg            Missense (heterozygous state)           hemochromatosisb                                        47
*All reported ferroportin mutations are at the heterozygous state (autosomal dominant trait). aReported data do not allow a classic Ferroportin Disease phenotype to be
assigned. bPatients carrying a ferroportin missense mutation in whom a classic hemochromatosis phenotype is confirmed by a liver biopsy.
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diagnosis of FD (Figure 4). First, common causes of hyper-
ferritinemia, such as metabolic disorders, inflammation,
cancer, etc., should be considered. If they are not found, or
if the hyperferritinemia persists after their treatment, the
next step depends on whether or not anemia is present. In
the absence of overt anemia, if liver and spleen iron con-
tent are increased at MRI or liver biopsy shows prominent
Kupffer cell iron load, FD disease should be considered
and genetic testing performed for confirmation of diagno-
sis (Figure 4). Another common cause of hereditary hyper-
ferritinemia with normal TS associated with iron accumu-
lation and anemia is Gaucher disease, usually associated
with hepatosplenomegaly, cytopenia, abnormal coagula-
tion, bone disease, and neuropathic manifestations.107 
In the absence of body iron accumulation, but in the
presence of elevated SF levels and normal TS, autosomal
dominant hyperferritinemia with cataract (due to muta-
tions of the iron responsive element in the 5' untranslated
region of the L ferritin mRNA108) or without cataract,109
should be considered. If overt anemia is present, but TS is
normal/low, aceruloplasminemia should be suspected, a
rare autosomal recessive disease due to loss of function
mutations in ceruloplasmin (CP) and resulting in iron over-
load in the liver and pancreas, and progressive neurode-
generation, diabetes and retinal degeneration.110
Brain MRI with typical iron accumulation in basal gan-
glia and thalamus may help confirm the diagnosis.  As
mentioned above, another rare genetic disease presenting
with hyperferritinemia and anemia is atransferrinemia/
hypotransferrinemia111 which, however, is characterized
by increased transferrin saturation due to extremely low
serum transferrin levels. 
Differential diagnosis mainly includes the classic (HFE)
and non-classic (TfR2, HAMP, HJV and FPN1) forms of
HH, all characterized by early and progressive increase of
TS followed by elevation of serum ferritin as iron accumu-
lation increases in parenchymal cells of the liver, pancreas,
heart and other organs (Table 2). As discussed, unlike HH,
in FD clinical expressivity is milder. 
Abdominal MRI is a useful non-invasive tool to catego-
rize and diagnose the disorder, as it can differentiate
patients with FD, characterized by the SSL triad (spleen,
spine, liver) iron retention (Figure 5B), from all other forms
of HH, including FPN1-HC, associated with liver iron
Ferroportin Disease
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Figure 2. The basis for abnormal iron transfer
into the bloodstream in Ferroportin Disease as
opposed to FPN-associated hereditary
hemochromatosis.
overload but normal spleen and bone marrow iron content
(Figure 5D).112
Treatment
Venesection is the cornerstone of therapy also in FD, but
it may not be tolerated equally in all patients, and low TS
with anemia may be rapidly established despite SF still
being elevated.1 Macrophage iron overload is very resist-
ant to iron withdrawal in this disorder, even in patients
who are apparently well-treated (Figure 5C). Therefore,
unlike HH, not only serum ferritin, but especially TS
should be carefully monitored during therapy. In addition,
therapy should not aim at reaching the usual HH targets
for iron depletion (TS below 20%, SF 50 ng/L or slight
anemia) but be more conservative.  There are no studies
on the optimal phlebotomy schedule in  FD. In practical
terms, a monthly/bi-monthly phlebotomy session for 1-2
years, depending on the underlying mutation, allows  an
acceptable state of iron depletion to be reached, while
maintenance therapy (usually a phlebotomy session every
4-6 months) should be continued for life. A reasonable tar-
get for therapy is an SF level of 100-200 ng/mL. In certain
cases, such Ft values may still reflect some iron loading of
tissue macrophages (Figure 5C), but the associated clinical
risk is negligible. Ideally, the optimal target is the lowest
acceptable ferritin level for TS and hemoglobin levels not
below the lower limit of normal. The (controversial)
dietary restrictions sometimes recommended for patients
with HH (avoiding vitamin C or iron-rich or enriched
foods) do not apply to  FD due to the different pathogenic
basis as compared to HH: normal/sufficient enterocyte
iron absorption and normal/marginally increased iron
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Table 4. Suspecting and diagnosing Ferroportin Disease.
                                                                                               When to suspect                                                         Essential for diagnosis
Sex               Ethnicity           Age, y                                               Signs                                               
Either                    Any                   10-80             • Unexplained hyperferritinemia and normal                             Heterozygosity for FPNmutation and 
                                                                                or inappropriately low transferrin saturation                           hyperferritinemia with normal or inappropriately
                                                                                • Isolated hyperferritinemia in father or mother                       low transferrin saturation and Kupffer  cell iron 
                                                                                • Sinusoidal (Kupffer cell) iron overload at liver                      overload at liver biopsy
                                                                                biopsy or spleen (and liver), iron accumulation 
                                                                                at MRI in patients with unexplained 
                                                                                hyperferritinemia and normal or inappropriately  
                                                                                low transferrin saturation                                                             
y: years; MRI: magnetic resonance  imaging. 
Figure 3. The different stages and outcomes of “iron retention” in  Ferroportin Disease versus “iron accumulation” in FPN1-associated hemochromatosis (HC).
Liver histology pictures are reproduced with the permission of  Sabelli et al.54
accumulation in parenchymal cells in the FD versus
increased iron absorption and marked iron accumulation
in parenchymal cells in HH. 
Iron chelation may be an option in selected cases.79
Siblings of patients with  FD, like their offspring, must
undergo screening since they have a 50% chance of being
susceptible. 
Conclusions
FPN1 is a multipass membrane iron-exporter that has
evolved in mammals to assure sufficient iron delivery
from the external milieu and internal sites of iron storage
and recycling to the bloodstream, mainly to support the
erythron activity. Overall, the FPN1/SLC40A1 gene is
essential for humans and total loss (homozygote muta-
tion) of its product is incompatible with life.49 Loss-of-
function of one FPN1 allele in humans results in  FD, char-
acterized by a preserved intestinal iron export activity but
compromised iron export from tissue macrophages. This
leads to progressive iron retention in liver, spleen and bone
marrow macrophages, resulting in inappropriately low
iron delivery to circulating transferrin and marginal iron-
restricted erythropoiesis that may result in overt anemia
when bone marrow demands are increased (e.g. menar-
che, aggressive phlebotomy regimen). Gain-of-function
mutations of FPN1 preclude the inhibitory activity of hep-
cidin, thereby leading to unrestricted iron transfer to the
bloodstream and  causing a rare form of HH.
The pathogenic, biochemical and clinical signatures of
FD are symmetrical and opposite to HFE and non HFE-
HH: normal/sufficient enterocyte iron absorption,
marked iron accumulation in non parenchymal cells in
Ferroportin Disease
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Figure 4.Diagnostic algorithm for Ferroportin Disease and hereditary hyperferritinemia. ACD/AI: anemia of chronic disease/anemia of inflammation. *Gaucher dis-
ease may present with or without siderosis depending on the disease stage. **Advanced ACD/AI may also present with siderosis at MRI (usually spleen and bone
marrow).
the FD versus increased iron absorption and marked iron
accumulation in parenchymal cells in HH; hyperferritine-
mia with normal/low transferrin saturation in FD versus
hyperferritinemia and high transferrin saturation in HH;
intolerance to aggressive phlebotomy regimens in  FD
versus optimal response to intense phlebotomy in HH;
mild and benign clinical course in  FD versus potentially
severe clinical expressivity in HH; vertical hereditary
transmission and presentation at each generation of  FD
versus recessive transmission of most forms of HH
(except FPN1-HH). 
While the molecular pathogenesis of  FD is becoming
more and more defined, the long-term effect of massive
iron retention in tissue macrophages in the setting of
chronic inflammatory/infectious or degenerative disor-
ders is still unclear. 
Today, isolated or unexplained hyperferritinemia rep-
resents one of the commonest reasons for referral.
Knowing that  FD is one of the most frequent genetic
causes of hyperferritinemia, regardless of ethnicity, it is
important to maintain a high diagnostic suspicion for
this disorder.
A. Pietrangelo
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